Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Judy Lytle"'
Publikováno v:
npj Parkinson's Disease, Vol 8, Iss 1, Pp 1-9 (2022)
Abstract Maintaining consistent levodopa benefits while simultaneously controlling dyskinesia can be difficult. Recently, an amantadine delayed release/extended release (DR/ER) formulation (Gocovri®) indicated for dyskinesia received additional FDA
Externí odkaz:
https://doaj.org/article/b1df00da4e004601b9e0f076c7438b58
Autor:
Rajesh Pahwa, Susan Fox, Robert A. Hauser, Stuart Isaacson, Judy Lytle, Reed Johnson, Lily Llorens, Andrea E. Formella, Caroline M. Tanner
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
BackgroundThe Unified Dyskinesia Rating Scale (UDysRS) evaluates dyskinesia in patients with Parkinson's disease (PD). A minimal clinically important change (MCIC)—the smallest change in a treatment outcome that a patient considers important—rema
Externí odkaz:
https://doaj.org/article/60ab47d041314b1e880ed7fc676425fc
Autor:
Rajesh, Pahwa, Susan, Fox, Robert A, Hauser, Stuart, Isaacson, Judy, Lytle, Reed, Johnson, Lily, Llorens, Andrea E, Formella, Caroline M, Tanner
BackgroundThe Unified Dyskinesia Rating Scale (UDysRS) evaluates dyskinesia in patients with Parkinson's disease (PD). A minimal clinically important change (MCIC)—the smallest change in a treatment outcome that a patient considers important—rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f83b11b6bc722512075305e8cd7f98c
https://escholarship.org/uc/item/7649q3c7
https://escholarship.org/uc/item/7649q3c7
Publikováno v:
NPJ Parkinson's disease, vol 8, iss 1
Maintaining consistent levodopa benefits while simultaneously controlling dyskinesia can be difficult. Recently, an amantadine delayed release/extended release (DR/ER) formulation (Gocovri®) indicated for dyskinesia received additional FDA approval